If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

Share Price is delayed by 15 minutes
Get Live Data
0.375    0.00 (0.00%)
Bid:
0.35
Ask:
0.40
Spread: 0.05 (14.286%)
Market Cap: £11.20m
VRCI Live PriceLast checked at - London Stock Exchange

Intraday Verici Dx Share Chart

Net Asset Value(s)

26 Jan 2022 16:28

RNS Number : 7538Z
China Post Global
26 January 2022
 

 

FUND:

MARKET ACCESS NYSE ARCA GOLD BUGS INDEX UCITS ETF

DEALING DATE:

25/01/2022

NAV PER SHARE:

 

 

EUR 92.9912

GBP 77.6544

NUMBER OF SHARES IN ISSUE:

813,533

CODE:

GOLB

ISIN:

LU0259322260

 

 

FUND:

MARKET ACCESS ROGERS INTERNATIONAL COMMODITY INDEX UCITS ETF

DEALING DATE:

25/01/2022

NAV PER SHARE:

 

 

EUR 24.8409

GBP 20.7440

NUMBER OF SHARES IN ISSUE:

3,125,122

CODE:

RICI

ISIN:

LU0249326488

 

 

FUND:

MARKET ACCESS STOXX CHINA A MINIMUM VARIANCE INDEX UCITS ETF

DEALING DATE:

26/01/2022

NAV PER SHARE:

 

 

EUR 115.9559

GBP 96.8316

NUMBER OF SHARES IN ISSUE:

238,711

CODE:

M9SV

ISIN:

LU1750178011

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NAVQQLFLLFLLBBD
Date   Source Headline
29th Sep 20237:00 amRNSHalf-year Report
20th Jul 20237:00 amRNSCLIA Certificate of Compliance update
6th Jul 20237:00 amRNSInvestor Presentation
3rd Jul 20237:00 amRNSSuccessful clinical validation of Clarava™
29th Jun 20234:57 pmRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
5th Jun 20237:01 amRNS2022 Annual Results
5th Jun 20237:00 amRNSProposed US pricing for Tutivia™
31st May 20237:00 amRNSNotice of Results
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
24th Apr 20237:00 amRNSFinal results timing
28th Mar 202311:05 amRNSSecond Price Monitoring Extn
28th Mar 202311:00 amRNSPrice Monitoring Extension
28th Mar 20239:05 amRNSSecond Price Monitoring Extn
28th Mar 20239:00 amRNSPrice Monitoring Extension
27th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 20237:00 amRNSOperational Update
21st Mar 20234:40 pmRNSSecond Price Monitoring Extn
21st Mar 20234:35 pmRNSPrice Monitoring Extension
13th Mar 20237:00 amRNSStatement re. Silicon Valley Bank
9th Mar 20237:00 amRNSTwo key patents granted in the US
2nd Mar 20237:00 amRNSCLIA Certificate of Compliance
27th Feb 20232:00 pmRNSPrice Monitoring Extension
7th Dec 20227:00 amRNSDirector/PDMR Shareholding
1st Dec 20226:07 pmRNSCorrection: Holding(s) in Company
3rd Oct 20227:00 amRNSProduct rebranding as Tutivia™
7th Sep 20227:00 amRNSHalf-year Report
6th Sep 20227:00 amRNSPositive results for Clarava from validation study
5th Sep 20227:00 amRNSNotice of Results
2nd Sep 20224:41 pmRNSSecond Price Monitoring Extn
2nd Sep 20224:35 pmRNSPrice Monitoring Extension
27th Jun 20223:17 pmRNSResult of AGM and voting results
24th Jun 20227:00 amRNSHolding(s) in Company
20th Jun 20227:30 amRNSDistribution of Verici Dx shares by EKF
16th Jun 20227:00 amRNSInvestor Presentation
15th Jun 202210:57 amRNSCEO Video Interview
14th Jun 20229:00 amRNSFurther data from Tuteva™ validation study
9th Jun 20227:00 amRNSCommercial Team Appointments
25th May 202212:00 pmRNSPosting of Annual Report & Accounts
19th May 20227:00 amRNSFinal Results
12th May 20227:00 amRNSResults of Tuteva™ clinical validation study
1st Apr 20227:00 amRNSClinical Validation Study Update
23rd Mar 20226:12 pmRNSHolding(s) in Company
21st Mar 20227:00 amRNSHolding(s) in Company
18th Mar 20225:13 pmRNSHolding(s) in Company
16th Mar 20223:33 pmRNSHolding(s) in Company
15th Mar 20224:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.